Fortress Biotech Files SC 13D/A for Checkpoint Therapeutics

TL;DR

Fortress Biotech updated its stake in Checkpoint Therapeutics. Watch this space.

AI Summary

Fortress Biotech, Inc. has filed an amendment (Amendment No. 8) to its Schedule 13D concerning Checkpoint Therapeutics, Inc. The filing, dated October 1, 2024, indicates changes in beneficial ownership. Fortress Biotech, Inc. is listed as the filer, with its principal executive offices located in Bay Harbor Islands, FL.

Why It Matters

This filing updates ownership information for Checkpoint Therapeutics, Inc., which could signal changes in control or strategic direction for the company.

Risk Assessment

Risk Level: medium — Schedule 13D filings often indicate significant changes in beneficial ownership, which can lead to increased volatility and potential shifts in corporate control.

Key Players & Entities

• Fortress Biotech, Inc. (company) — Filer of the Schedule 13D/A
• Checkpoint Therapeutics, Inc. (company) — Subject company of the Schedule 13D/A
• Lindsay A. Rosenwald, M.D. (person) — Contact person for Fortress Biotech, Inc.

FAQ

Key Financial Figures

• $0.0001 — INC. (Name of Issuer) Common Stock, $0.0001 Par Value Class A Common Stock, $0.00
• $1.29 — rrants, which have an exercise price of $1.29 per share, are exercisable until July 1

Filing Documents

• tm2425299d1_sc13da.htm (SC 13D/A) — 50KB
• 0001104659-24-104932.txt ( ) — 51KB

and the Warrants in Footnote 1 above

Item 3 and the Warrants in Footnote 1 above. Item 7. Materials to be Filed as Exhibits. Exhibit 7.01 Amended and Restated Certificate of Incorporation of Checkpoint Therapeutics, Inc., dated March 3, 2015, incorporated by reference to Exhibit 3.1 to the Form 10-12G filed by the Issuer with the SEC on July 11, 2016 (File No. 000-55506).* Exhibit 7.02 Amendment to the Amended and Restated Certificate of Incorporation of Checkpoint Therapeutics, Inc., dated June 14, 2018, incorporated by reference to Exhibit 10.1 to the Form 10-Q filed by the Issuer with the SEC on August 7, 2018 (File No. 001-38128).* Exhibit 7.03 Form of Amended and Restated Common Stock Warrant issued by Reporting Person to Dr. Rosenwald and Mr. Weiss for Issuer common stock, incorporated by reference to Exhibit 7.01 to the Schedule 13D filed by the Reporting Person with the SEC on May 26, 2017 (File No. 005-89990).* Exhibit 7.04 Amended and Restated Founders Agreement between Fortress Biotech, Inc. and Checkpoint Therapeutics, Inc. dated July 11, 2016 and effective as of March 17, 2015, incorporated by reference to Exhibit 10.2 to the Form 10-12G filed by the Issuer with the SEC on July 11, 2016 (File No. 000-55506).* Exhibit 7.05 First Amendment to the Amended and Restated Founders Agreement between Fortress Biotech, Inc. and Checkpoint Therapeutics, Inc. dated October 5, 2017, incorporated by reference to Exhibit 10.2.1 to the Form 10-K filed by the Issuer with the SEC on March 18, 2019 (File No. 001-38128).* * Previously Filed. CUSIP No. 162828 206 Page 7 of 7 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: October 1, 2024 FORTRESS BIOTECH, INC. By: /s/ David Jin Name: David Jin Title: Chief Financial Officer

View Full Filing

View this SC 13D/A filing on SEC EDGAR